NEW YORK, March 5, 2014 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Analysts Review released its analysts' notes regarding
Intuitive Surgical, Inc. (NASDAQ: ISRG), Agilent Technologies Inc.
(NYSE: A), Teleflex Incorporated (NYSE: TFX), WuXi PharmaTech
(Cayman) Inc. (NYSE: WX), and Pacira Pharmaceuticals Inc. (NASDAQ:
PCRX). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
--
Intuitive Surgical, Inc. Analyst
Notes
On March 3, 2014, Intuitive
Surgical, Inc.'s (Intuitive Surgical) stock went up by 2.03% to
$453.84. In the past three trading
days, Intuitive Surgical's shares declined 3.53%, compared to the
Nasdaq Composite Index which went down by 0.34% during the same
trading period. The full analyst notes on Intuitive Surgical, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/03052014/ISRG/report.pdf
--
Agilent Technologies Inc. Analyst
Notes
On March 3, 2014, Agilent
Technologies Inc. (Agilent Technologies) reported that its
tissue-based cancer diagnostics business, Dako, is the official
Platinum Sponsor of 2014 annual meeting of the United States and Canadian Academy of
Pathology (USCAP) at the San Diego
Convention Center in San Diego,
California. According to the Company, Dako will showcase its
entire portfolio of integrated pathology solutions, designed with
pathologists and laboratory staff in mind, at the exhibition booth
No. 552. Commenting on the update, Britt Meelby Jensen, Dako's
General Manager and Agilent Technologies' Vice President, stated,
"Dako is proud to once again be the official Platinum Sponsor of
the USCA. This is one of the best-organized and most-attended
pathology congresses, and we see it as a key opportunity to reach
the pathology community. We look forward to meeting with the many
attendees who share our commitment to the fight against cancer."
The full analyst notes on Agilent Technologies Inc. are available
to download free of charge at:
http://www.AnalystsReview.com/03052014/A/report.pdf
--
Teleflex Incorporated Analyst
Notes
On February 25, 2014, Teleflex
Incorporated (Teleflex) reported that its Chairman, President and
CEO, Benson F. Smith, is scheduled
to speak at the Barclays Global Healthcare Conference on
March 11, 2014, at the Loews Hotel,
starting at 3:15 p.m. ET.
Additionally, Teleflex stated that an audio webcast and
accompanying slide presentation of the event will be made available
on the Company's website under the investor section. The full
analyst notes on Teleflex Incorporated are available to download
free of charge at:
http://www.AnalystsReview.com/03052014/TFX/report.pdf
--
WuXi PharmaTech (Cayman) Inc. Analyst
Notes
On February 26, 2014, WuXi
PharmaTech (Cayman) Inc. (WuXi PharmaTech) announced that Dr. Hua
Mu has joined the Company as Senior Vice President of Operations
and Global Head of the Product Development Service and Partnership
Business Unit. According to the Company, in the new role Dr. Hua Mu
will report to Dr. Ge Li, Chairman
and CEO of WuXi PharmaTech. Commenting on the appointment, Dr. Li
stated, "I am delighted to welcome Hua to WuXi's leadership team.
Hua brings extensive experience, particularly in clinical
development in China, that is very
critical for WuXi to help our partners bring their innovations to
China and to develop innovative
drugs to benefit Chinese patients." The full analyst notes on WuXi
PharmaTech (Cayman) Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03052014/WX/report.pdf
--
Pacira Pharmaceuticals Inc. Analyst
Notes
On February 27, 2014, Pacira
Pharmaceuticals Inc. (Pacira) announced that the Phase 3 clinical
trial assessing the safety and efficacy of EXPAREL® (bupivacaine
liposome injectable suspension) in femoral nerve block for total
knee arthroplasty met its primary efficacy endpoint. According to
Pacira, the Phase 3 trial evaluated 183 patients who were
randomized to receive either 266 mg of EXPAREL or placebo, with all
patients offered rescue narcotics as needed. Commenting on the
results of the trial, Dave Stack,
President, CEO and Chairman of Pacira, stated, "We are pleased to
report the positive results of the femoral nerve block trial and
look forward to filing for a nerve block indication. We believe
that the expansion of the EXPAREL label to include nerve block will
further enhance its clinical utility and broaden its access among
anesthesiologists and surgeons." The full analyst notes on Pacira
Pharmaceuticals Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03052014/PCRX/report.pdf
----
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review